Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:

NCT ID: NCT05509374 Recruiting - Multiple Myeloma Clinical Trials

Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone

KMM2002
Start date: October 28, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the evaluate the efficacy and safety of administering a combination of carfilzomib, pomalidomide, and dexamethasone in patients with relapsed or advanced multiple myeloma after carfilzomib, lenalidomide, and dexamethasone therapy.

NCT ID: NCT05503550 No longer available - Clinical trials for Relapsed or Refractory Multiple Myeloma

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.

NCT ID: NCT05498545 Not yet recruiting - Clinical trials for Relapsed/Refractory Multiple Myeloma

Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

Start date: September 2022
Phase: Phase 1
Study type: Interventional

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Universal BCMA-targeted LUCAR-B68 Cells Product in Patients With Relapsed/Refractory Multiple Myeloma

NCT ID: NCT05497804 Recruiting - Multiple Myeloma Clinical Trials

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Start date: September 22, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help determine if patients who have a small amount of cancer left after the initial treatment, called minimal residual disease, will benefit from the drug combination.

NCT ID: NCT05497102 Recruiting - Multiple Myeloma Clinical Trials

Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT

KMM1911
Start date: November 8, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of salvage treatment with carfilzomib/lenalidomide/dexamethasone (KRD) followed by 2nd autologous stem cell transplantation (ASCT) and lenalidomide maintenance in patients with relapsed myeloma after 1st ASCT.

NCT ID: NCT05495620 Not yet recruiting - Clinical trials for Multiple Myeloma in Relapse

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Start date: August 1, 2022
Phase:
Study type: Observational

Research question: Is KRd therapy effective and safe in the real-world Asian patients? Primay objective: To evaluate the effectiveness of KRd in RRMM patients Secondary objectives: To evaluate the effectiveness of investigational treatment strategy by - PFS difference according to the high-risk disease subgroups and previous treatment - OS - Overall response rate and clinical benefit rate - Duration of response To evaluate the safety and tolerability of KRd in RRMM patients

NCT ID: NCT05493800 Active, not recruiting - Multiple Myeloma Clinical Trials

Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT

Capella
Start date: February 1, 2022
Phase: Phase 2
Study type: Interventional

Evaluate the efficacy and safety for the prevention of oral mucositis and PK of MIT-001 for lymphoma or multiple myeloma patients receiving conditioning chemotherapy for autologous hematopoietic stem cell transplantation(auto-HSCT).

NCT ID: NCT05493618 Withdrawn - Clinical trials for Multiple Myeloma, Refractory

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

Start date: December 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.

NCT ID: NCT05490771 Active, not recruiting - Clinical trials for Refractory Multiple Myeloma

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Start date: June 20, 2018
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of copanlisib hydrochloride (copanlisib) in patients whose cancer has a genetic change called PIK3CA mutation. Copanlisib may stop the growth of cancer cells by blocking PIK3, a protein needed for cell growth. Researchers hope to learn if copanlisib will shrink this type of cancer or stop its growth.

NCT ID: NCT05486975 Recruiting - Clinical trials for Relapsed and/or Refractory Multiple Myeloma

This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.

Start date: August 10, 2022
Phase: Early Phase 1
Study type: Interventional

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0591CP in patients with relapsed and/or refractory multiple myeloma.